Jeffrey Lawson
Rheumatology · Greenville, SCNPI 1790869147
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 878 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,131 and has fallen 98.2% since, to $74 in 2025.
Across 878 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Johnson & Johnson$1K
- AbbVie$1K
- GSK$1K
- Pfizer$1K
- UCB, Inc.$1K
- plus $6K from 29 others
Across 170 payments — averaging $2095.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sun Pharmaceutical Industries Inc.$189K
- Novartis$120K
- Amgen$28K
- AbbVie$10K
- Pfizer$7K
- Eli Lilly$1K
What the payments were for
- Food & beverage$14,88799%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 174 | $2,685 |
| Johnson & Johnson | 99 | $1,352 |
| AbbVie | 58 | $1,283 |
| GSK | 47 | $1,122 |
| Pfizer | 96 | $1,074 |
| UCB, Inc. | 67 | $1,038 |
| E.r. Squibb & Sons, L.L.C. | 55 | $885 |
| Novartis | 41 | $640 |
| AstraZeneca(2 entities) | 22 | $592 |
| Boehringer Ingelheim | 26 | $556 |
| Mallinckrodt Hospital Products Inc. | 26 | $517 |
| Lilly USA, LLC | 35 | $515 |
| Mallinckrodt Enterprises LLC | 18 | $323 |
| Aurinia Pharma U.S., Inc. | 11 | $274 |
| Sanofi | 8 | $268 |
| Bristol Myers Squibb | 8 | $239 |
| Genentech USA, Inc. | 13 | $231 |
| ANI Pharmaceuticals, Inc. | 8 | $210 |
| Regeneron Healthcare Solutions, Inc. | 12 | $207 |
| Organon | 11 | $173 |
| Actelion Pharmaceuticals US, Inc. | 9 | $122 |
| Boston Scientific | 1 | $117 |
| Bioventus LLC | 6 | $93 |
| Radius Health, Inc. | 5 | $89 |
| Merck | 6 | $76 |
| Pacira Therapeutics, Inc. | 3 | $61 |
| Abbott | 2 | $50 |
| Ultragenyx Pharmaceutical Inc. | 3 | $50 |
| Tersera Therapeutics LLC | 2 | $34 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Sandoz | 1 | $21 |
| Avanos Medical | 1 | $15 |
| Fidia Pharma USA Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Medexus Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,972 in reported general payments places this provider in the 70th percentile of 123 rheumatology providers in South Carolina.
Other rheumatology in Greenville
- Alan BrownGreenville$947K
- Long Huynh-DucGreenville$278K
- Corey EphrussiGreenville$54K
- Suhail KumarGreenville$23K
- Richard KimGreenville$20K
- Gulzar MerchantGreenville$18K
- Ezinma EzealahGreenville$12K
- Stephen MullisGreenville$8K
- Corwin McGeeGreenville$5K
- Muthamma MachimadaGreenville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.